HSK-21542 is under clinical development by Sichuan Haisco Pharmaceutical and currently in Phase III for Post-Operative Pain. According to GlobalData, Phase III drugs for Post-Operative Pain have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how HSK-21542’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HSK-21542 is under development for the treatment of chronic itching, uremic pruritus, post-operative pain in subjects undergoing laparoscopic surgery, urotoxicosis (unspecified toxic disorder) and liver cancer. The drug candidate acts by targeting opioid kappa receptor. It is administered through intravenous bolus and oral route.
Sichuan Haisco Pharmaceutical overview
Sichuan Haisco Pharmaceutical (Haisco) is pharmaceutical company. The company’s areas of interests include drug development, manufacturing, and sales. Haisco is headquartered in Chengdu, Sichuan, China.
For a complete picture of HSK-21542’s drug-specific PTSR and LoA scores, buy the report here.